BLCO Stock Forecast & Price Target

Bausch & Lomb demonstrated strong revenue growth across all three segments in the third quarter of 2025, with Vision Care, Surgical, and Pharmaceuticals generating 8%, 4%, and 8% year-over-year growth, respectively, leading to overall revenue of $1.281 billion and a constant currency growth of 6%. The notable performance of the MIEBO product, showcasing a remarkable 110% year-over-year prescription growth, highlights its potential to become a market leader in the dry eye category, particularly given its unique approval for treating the evaporative component of dry eye. Furthermore, the company's ability to limit net loss to $28 million, significantly better than previous estimates, reinforces a positive trajectory for future financial performance as management reiterated 2025 guidance, indicating a commitment to continued growth.

The analysis of Bausch & Lomb's stock presents several fundamental challenges that contribute to a negative outlook. The company faces significant competition in the ophthalmology market, which presents hurdles in maintaining its market leadership and may adversely affect revenue growth, particularly in elective procedures like cataract surgeries and the premium contact lens segment. Additionally, high leverage from a previous acquisition could restrict the company's ability to pursue further M&A opportunities for growth, while a limited product pipeline and uncertainty regarding the separation from its parent company could deter investor confidence.